No significant analgesic benefit of liposomal bupivacaine over bupivacaine HCl for PAI in TJA
Periarticular Injection of Liposomal Bupivacaine Offers No Benefit Over Standard Bupivacaine in Total Knee Arthroplasty: A Prospective, Randomized, Controlled Trial
J Arthroplasty. 2017 Feb;32(2):628-634162 patients scheduled for total knee arthroplasty were randomized to postoperative analgesia using periarticular injection analgesia containing either liposomal bupivacaine or standard bupivacaine HCl. The purpose of this study was to determine if the use of liposomal bupivacaine was associated with significantly lower perioperative pain scores. Results demonstrated no significant differences between groups in average daily pain, worst daily pain, or least daily pain over the first 24 hours after surgery and over the first 4 days postoperatively. Narcotic consumption also did not significantly differ between groups.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
